Evelo Biosciences, Inc (EVLO)

Etorro trading 970x250
Evelo Biosciences, Inc (EVLO) Logo

About Evelo Biosciences, Inc

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Address: 620 Memorial Drive, Cambridge, MA, United States, 02139

Evelo Biosciences, Inc News and around…

Latest news about Evelo Biosciences, Inc (EVLO) common stock and company :

CORRECTION: Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights
12 May, 2022 Yahoo! Finance

CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, May 12 by Evelo Biosciences, Inc. (Nasdaq: EVLO), please note that in the first sentence of the First Quarter 2022 Financial Results (Unaudited) section, the dates should be “As of March 31, 2022, cash and cash equivalents were $39.6 million, as compared to cash and cash equivalents of $68.4 million as of December 31, 2021,” not December 31, 2021 and March 31, 2021. The corrected release f

Evelo Biosciences: Q1 Earnings Insights
12 May, 2022 FinancialContent

Evelo Biosciences (NASDAQ:EVLO) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:00 AM. Here's what ...

Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights
12 May, 2022 Yahoo! Finance

CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today reported financial results and business highlights for the first quarter 2022. “This quarter we reported positive data for EDP1815 in psoriasis in three key areas: effects on systemic inflammatory cytokine markers; depth and duration of response at 6-month follow-up post dosing; and increased target site e

80 Biggest Movers From Yesterday
04 May, 2022 FinancialContent

Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 93.1% to close at $6.45 on Tuesday on above-average volume. XORTX ...

55 Biggest Movers From Friday
25 Apr, 2022 FinancialContent

Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals ...

Evelo Biosciences Appoints John Maraganore, Ph.D. and Tassos Gianakakos as Strategic Advisors
21 Apr, 2022 Yahoo! Finance

CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that John Maraganore, Ph.D., founder and longtime former CEO of Alnylam Pharmaceuticals, and Tassos Gianakakos, the longtime former CEO of MyoKardia, have joined Evelo as strategic advisors. “We are thrilled to welcome both John and Tassos as strategic advisors to Evelo,” said Simba Gill, Ph.D.,

Adding Up The Components: Russell 2000 Could Rise 35%
19 Apr, 2022 FinancialContent

The financial media loves to get predictions from experts about where they think a given stock market index is headed. Some experts look at technical analysis patterns, others look at valuation metrics, others apply a broad macro view of the economy..

Read Why Did Evelo Discontinue EDP1867 Atopic Dermatitis Program
14 Apr, 2022 FinancialContent

Evelo Biosciences Inc(NASDAQ: EVLO) willput the EDP1867 program on holdafter completing a Phase 1 clinical trial in ...

Evelo Biosciences Provides Updated Guidance on Advancing Clinical Inflammation Programs
14 Apr, 2022 Yahoo! Finance

–Guidance on registration trials for EDP1815 in psoriasis expected in 3Q 2022––Data from initial cohort of patients in Phase 2 trial of EDP1815 in atopic dermatitis expected 1Q 2023––Faster release capsule cohort to be added to on-going Phase 2 trial of EDP1815 in atopic dermatitis; data expected 1H 2023– CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally deliv

Evelo Biosciences Announces Appointments of Jose-Carlos Gutiérrez-Ramos and Tonya Williams to Board of Directors
06 Apr, 2022 Yahoo! Finance

CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointment of Jose-Carlos Gutiérrez-Ramos, Ph.D., and Tonya Williams, J.D., to its Board of Directors. “We are delighted to welcome Jose-Carlos back to our Board. He is one of the world's preeminent drug discovery and immunology leaders, and has vast experience across both large pharmaceuti

Evelo Biosciences Presents Late-Breaking Oral Abstract on Data from Phase 2 Trial of EDP1815 in Psoriasis at 2022 American Academy of Dermatology Annual Meeting
26 Mar, 2022 Yahoo! Finance

CAMBRIDGE, Mass., March 26, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today presented a late-breaking oral abstract on data from a Phase 2 trial of EDP1815 in psoriasis at the 2022 American Academy of Dermatology (AAD) Annual Meeting, being held March 25-29 in Boston, Massachusetts. “We are proud to join the dermatology community at

63 Biggest Movers From Yesterday
25 Mar, 2022 FinancialContent

Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares gained 39.1% to close at $1.05 on Thursday. The company recently said its ...

Mid-Afternoon Market Update: Nasdaq Rises 150 Points; Emclaire Financial Shares Spike Higher
24 Mar, 2022 FinancialContent

U.S. stocks traded higher toward the end of trading, with the Nasdaq composite gaining over 150 points on Thursday. The Dow traded up ...

12 Health Care Stocks Moving In Thursday's Intraday Session
24 Mar, 2022 FinancialContent

Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV) stock increased by 26.3% to $1.73 during Thursday's regular session. ...

Evelo Biosciences, Inc. (EVLO) Q4 2021 Earnings Call Transcript
24 Mar, 2022 FinancialContent

EVLO earnings call for the period ending December 31, 2021.

Evelo Biosciences Shares Gain After Positive Data On Faster Release EDP1815 Capsule, Q4 Earnings
24 Mar, 2022 FinancialContent

In the Q4 earnings release,Evelo Biosciences Inc(NASDAQ: EVLO) shared results from an ongoing Phase 1 single-center trial in ...

Mid-Day Market Update: Dow Surges 250 Points; LiqTech International Shares Slide
24 Mar, 2022 FinancialContent

U.S. stocks traded higher midway through trading, with the Dow Jones jumping 250 points on Thursday. The Dow traded up 0.75% to ...

34 Stocks Moving In Thursday's Mid-Day Session
24 Mar, 2022 FinancialContent

Gainers JX Luxventure Limited (NASDAQ: LLL) shares jumped 37.7% to $4.64. Emclaire Financial Corp (NASDAQ: EMCF) shares ...

The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
24 Mar, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Novartis Announces FDA ...

Evelo Biosciences: Q4 Earnings Insights
24 Mar, 2022 FinancialContent

Evelo Biosciences (NASDAQ:EVLO) reported its Q4 earnings results on Thursday, March 24, 2022 at 06:00 AM. Here's what ...

Evelo Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
24 Mar, 2022 Yahoo! Finance

–Oral presentation on EDP1815 Phase 2 data in psoriasis accepted in late-breaking abstract session at AAD on Saturday, March 26, 2022 ––Positive data reported on faster release capsule––Phase 2 data from EDP1815 in atopic dermatitis on-track for 1H 2023 readout––Management to host conference call at 8:30 a.m. ET– CAMBRIDGE, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of ora

Earnings Scheduled For March 24, 2022
24 Mar, 2022 FinancialContent

Companies Reporting Before The Bell • iHuman (NYSE:IH) is likely to report earnings for its fourth quarter. • ...

Evelo Biosciences's Earnings Outlook
23 Mar, 2022 FinancialContent

Evelo Biosciences (NASDAQ:EVLO) is set to give its latest quarterly earnings report on Thursday, 2022-03-24. Here's what investors need ...

The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
20 Mar, 2022 FinancialContent

Biotech stocks rebounded along with the broader market in the week endingMarch 18, as risk appetite returned. Multiple conference ...

Evelo Biosciences Q4 2021 Earnings Conference Call On March 24, 2022 At 08:30 AM ET
18 Mar, 2022 FinancialContent

Evelo Biosciences (NASDAQ:EVLO) will host a conference call at 08:30 AM ET on March 24, 2022, to discuss Q4 2021 earnings results. How ...

Evelo Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
17 Mar, 2022 Yahoo! Finance

CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 24, 2022 to report its fourth quarter and full year 2021 financial results and discuss business highlights. To access the live conference call, please dial 866-7

Evelo Biosciences to Host KOL Discussion on Treatment Advances for All Stages of Psoriasis and Potential of SINTAX Medicines
07 Mar, 2022 Yahoo! Finance

CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that it will host a virtual event titled, “The Future: A no regrets treatment for all stages of psoriasis and broader inflammatory disease.” The event will be held virtually on Friday, March 11, 2022, beginning at 8:00 a.m. ET. During the event, mem

Why Evelo Biosciences (EVLO) Might Surprise This Earnings Season
02 Mar, 2022 Yahoo! Finance

Evelo Biosciences (EVLO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Evelo Biosciences to Participate in Cowen 42nd Annual Health Care Conference
02 Mar, 2022 Yahoo! Finance

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that Simba Gill, Ph.D., Chief Executive Officer of Evelo, will participate in a panel discussion titled “GI/Microbiome” at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9th, 2022 at 10:30 a.m. ET. A live audio webcast of the panel

Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs
28 Feb, 2022 Yahoo! Finance

Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to ad

Evelo Biosciences, Inc (EVLO) is a NASDAQ Common Stock listed in , ,

970x250